Corrections

An article in the Oct. 20 issue of BioWorld Today should have said the number of patients in the Phase III trial of Agenerase, a HIV protease inhibitor developed by Vertex Pharmaceuticals Inc., was 850.

An "Appointments & Advancements" item in the Oct. 15 issue of BioWorld Today should have said Rigel Inc., of Sunnyvale, Calif., named Brian Cunningham chief operating officer.